Intellia Therapeutics (NTLA) Misses Q4 EPS by 9c, Revenues Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. WCN
7. SPOT
8. SPY
9. FIX
10. TSCO

Go back to Intellia Therapeutics (NTLA) Misses Q4 EPS by 9c, Revenues Miss

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2020 Financial Results

February 25, 2021 7:30 AM EST

Expects to report initial data from Phase 1 study of NTLA-2001, a potentially curative single-course therapy for transthyretin amyloidosis (ATTR), in 2021On track to submit an IND or IND-equivalent in mid-2021 for NTLA-5001 for the treatment of acute myeloid leukemia (AML)Intends to submit an IND or IND-equivalent in 2H 2021 for NTLA-2002 for the treatment of hereditary angioedema (HAE) Plans to nominate at least one new development candidate in 2021 from broad research efforts and continued platform... More